Disclosure of Shareholdings
23.06.2025 - 07:00:04Disclosure of Shareholdings. BB BIOTECH AG / CH0038389992
EQS Voting Rights Announcement: BB BIOTECH AG 23.06.2025 / 07:00 CET/CEST Dissemination of a Voting Rights Announcement transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Submited, 18/06/2026 Notification ID: 77b1d1cb-63b3-4b8f-b0f1-bb767e0006e7 Disclosure notification concerning a single investor Name of listed company BB Biotech AG PART 1: PERSON SUBJECT TO REPORTING OBLIGATION Last name, first name, place of residence or company name and head office of the beneficial owner (art. 120 para. 1 FMIA) and/ or of the person who has the discretionary power to exercise the voting rights (art. 120 para. 3 FMIA): Company: Saba Capital Management, L.P City: New York Country: United States of America (the) PART 2: IN CASE OF INDIRECT PARTICIPATION Last name, first name, place of residence or company name and head office of the person/s directly involved PART 3: DATE AND REASON FOR THE REPORTING OBLIGATION Date of the act that creates the obligation to notify: 17.06.2025 Facts and circumstances triggering the obligation to notify (art. 22 para. 1 b FMIO-FINMA): X Acquisition Sale Creation of a group Change in group composition Termination of a group Discretionary exercise of voting rights Securities lending and comparable transactions Exercise, non-exercise or expiration of derivative holdings Granting (writing) of derivative holdings Capital increase Capital reduction Ipso jure transfer or transfer due to a decision by a court or public authority Change in the information subject to the obligation to notify Other Total of voting rights below 3% If the participation falls below the threshold of 3% (purchase positions and sale positions), no indication in Part 4 or Part 5 is required. Total of voting rights <3% PART 4: PURCHASE POSITIONS PURSUANT TO ART. 14 PARA. 1 A FMIO-FINMA Total of all purchase positions: Total of all equity securities or equity related securities (item 1), number of voting rights that can be exercised at one’s own discretion (item 3) and derivative holdings (item 4)
Equity securities or equity related securities
PART 5: SALE POSITIONS PURSUANT TO ART. 14 PARA. 1 B FMIO-FINMA Total of all sale positions: Basis of calculation (art. 14 para. 2 FMIO-FINMA): total number of voting rights pursuant to the entry in the commercial register (see Central Business Names Index) or Publication according to art. 115 para. 3 FMIO: 55,400,000 Derivative holdings Share sale rights (such as put-options according to art. 15 para. 2 a FMIO-FINMA), granted (written) conversion and share purchase rights and other derivative holdings:
23.06.2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
Language: | English |
Company: | BB BIOTECH AG |
Schwertstrasse 6 | |
8200 Schaffhausen | |
Switzerland | |
Internet: | www.bbbiotech.ch |
End of News | EQS News Service |
|